Published on 2nd June 2015
Biopharmaceutical company Scancell Holdings reported further encouraging results from the ongoing 'Phase 1/2' clinical trial of its melanoma treatment SCIB1, which it presented at the annual meeting of the American Society of Clinical Oncology in Chicago.
URL: http://www.digitallook.com/dl/news/story/22868068/...